Methyl 3-(cyclopropylmethoxy)-4-(methylsulfonamido)benzoate (also named as 3-Cyclopropylmethoxy-4-methanesulfonylaminobenzoic acid methyl ester) is typically used in the preparation of CHF6001, a novel highly potent and selective phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease (COPD).
Process development of the PDE4 inhibitor K-34.
CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration.
Synthesis of 14C- and 2H-labelled CHF6001: A new potent PDE4 inhibitor. 
 A.Yanagisawa, et al, Org. Process Res. Dev., 2011, 15(2), pp 376-381.
 N.Moretto, et al, J. Pharmcol. Exp. Ther., 2015, 352(3), pp 559-567.
 E.Fontana, et al, J. Label. Compd. Radiooharm., 2017, 60(12), pp 577-585.
NONH for all modes of transport
1. Product Specification
2. Safety Data Sheet
Please inquire for pricing and availability of this product by writing email email@example.com.